Artificial Intelligence for Head and Neck Squamous Cell Carcinoma: From Diagnosis to Treatment
American Society of Clinical Oncology Educational Book · 2025-06 · 45 (3)
DOI: 10.1200/edbk-25-472464 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Society of Clinical Oncology Educational Book, 2025-06. Verfasst von Bolin Song und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, Emory Empathetic AI for Health Institute, Georgia Institute of Technology and Emory University, Atlanta, GA. Hauptthemen laut MEDLINE: Artificial Intelligence, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 85 Literaturangaben. Gefördert von: BLRD VA.
Abstract (Originalsprache)
Head and neck squamous cell carcinoma (HNSCC) remains a globally prevalent malignancy with high morbidity and mortality. Despite therapeutic advances, patient outcomes are hindered by tumor heterogeneity, treatment-related toxicity, and the limitations of traditional prognostic tools. Artificial intelligence (AI) offers the opportunity to improve personalized HNSCC management by integrating complex radiologic, pathologic, and molecular data into actionable information insights. This review synthesizes recent developments in AI applications across the HNSCC care continuum, from diagnosis through treatment planning, emphasizing their clinical relevance and translational potential. AI has shown promise in enhancing diagnostic accuracy through automated tumor burden assessment, extranodal extension prediction, and endoscopic image analysis. Deep learning applied to radiology and digital pathology enables the extraction of prognostic features that may inform risk stratification and treatment de-escalation, particularly in human papillomavirus–associated oropharyngeal carcinoma. Multimodal AI models that fuse imaging, histopathology, and electronic health records have demonstrated superior performance in predicting survival outcomes compared with unimodal approaches. Additional applications include early toxicity detection during radiotherapy, adaptive treatment planning, and surgical complication forecasting. AI also holds potential in predicting immunotherapy response by identifying imaging and histologic correlates of tumor immunogenicity. Barriers to clinical translation remain, and continued development of explainable models, prospective trials, and seamless integration into clinical workflows will be critical for broad adoption. AI has already begun to affect HNSCC radiotherapy and surgical planning, and with thoughtful implementation, it may enable safer, more personalized care across the HNSCC treatment landscape.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Biomedical Engineering, Emory Empathetic AI for Health Institute, Georgia Institute of Technology and Emory University, Atlanta, GA.
- Princess Margaret Cancer Centre University Health Network, Toronto, Canada.
- Artificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Boston, MA.
- Harvard Medical School, Boston, MA.
ORCID-Profile: Benjamin H Kann
Förderung
- BLRD VA
Zitieren
APA
Song, B., Yadav, I., Tsai, J. C., Madabhushi, A., & Kann, B. H. (2025). Artificial Intelligence for Head and Neck Squamous Cell Carcinoma: From Diagnosis to Treatment. American Society of Clinical Oncology Educational Book, 45(3). https://doi.org/10.1200/edbk-25-472464
Vancouver
Song B, Yadav I, Tsai JC, Madabhushi A, Kann BH. Artificial Intelligence for Head and Neck Squamous Cell Carcinoma: From Diagnosis to Treatment. American Society of Clinical Oncology Educational Book. 2025;45(3). doi:10.1200/edbk-25-472464
BibTeX
@article{Song2025,
author = {Song, Bolin and Yadav, Ipsa and Tsai, Jillian C and Madabhushi, Anant and Kann, Benjamin H},
title = {Artificial Intelligence for Head and Neck Squamous Cell Carcinoma: From Diagnosis to Treatment},
journal = {American Society of Clinical Oncology Educational Book},
year = {2025},
volume = {45},
number = {3},
doi = {10.1200/edbk-25-472464}
}
EUVIMED